Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
Updated 2026-09-18 · every price checked by hand
Fifty dollars a month. That is below the cheapest cash price we have found anywhere, for an FDA-approved product rather than a compounded one.
That is less than every cash-pay programme we track. The cheapest compounded tirzepatide on this site is Trimi at $125 a month and the cheapest semaglutide is SuperHealthy Rx at $85. A $50 copay undercuts both, for an FDA-approved product rather than a compounded one.
The arithmetic against cash pay
Our cheapest verified cash programme is $86 a month for semaglutide and $125 for tirzepatide. A $50 Medicare copay beats both, saves between $432 and $900 a year against them, and gets you an approved medication instead of a compounded preparation. If you are eligible, every other page on this site is the wrong page.
What was actually announced
CMS will give eligible Medicare beneficiaries access to certain GLP-1 medications for $50 for a monthly supply, beginning 1 July 2026 and running through 31 December 2027.
- It is a time-limited demonstration, not a permanent benefit — it is currently scheduled to end on 31 December 2027.
- You must be enrolled in a Medicare Part D prescription drug plan to be eligible.
- It covers certain GLP-1 medications; CMS has said it will publish more detail for beneficiaries as the programme begins.
- Separately, manufacturers agreed to price the injectable products at around $245 per month for Medicare, with beneficiary copays capped at $50.
- Whether a GLP-1 is appropriate for you is a decision for your doctor — eligibility for the programme is not the same as a clinical recommendation.
Announced in the CMS press release, 6 May 2026. CMS has published further detail at cms.gov, and says it will release more for beneficiaries as the programme starts.
The part people will miss. It is a demonstration with an end date — currently 31 December 2027. It is not a permanent Medicare benefit, and nobody should assume the $50 price continues past that without checking.
How it compares with paying cash
| Route | Monthly | FDA-approved? |
|---|---|---|
| Medicare GLP-1 Bridge (from 1 July 2026) | $50 | Yes |
| Cheapest compounded semaglutide (SuperHealthy Rx) | $85 | No — compounded |
| Cheapest compounded tirzepatide (Trimi) | $125 | No — compounded |
| Wegovy pill, self-pay | $149+ | Yes |
| Foundayo (orforglipron), self-pay | $149+ | Yes |
Separately, manufacturers agreed to price the injectable products at around $245 a month for Medicare, with beneficiary copays capped at $50. The two things together mean the cash-pay compounded market is no longer the obvious cheap option it was in 2024.
If you are not on Medicare
This programme will not help you, but the approved oral products might — both now start at $149 a month. We go through them in the FDA-approved pills. If you are still paying cash for a compounded injection, compare it against those before renewing.
Nothing here is medical advice, and we are not affiliated with CMS or Medicare. Check your own eligibility with Medicare directly and your treatment with your doctor.
Read next
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure